What is hyperthyroidism with infiltrative synostosis? Hyperthyroidism with infiltrative proptosis is closely related to hyperthyroidism and is a disease associated with endocrine and autoimmune conditions. These antigens stimulate lymphocytes to produce a large number of antibodies, including thyroid receptor antibody (TRAb), thyroid microsomal antibody (TMAb), thyroglobulin antibody (TGAb), etc. These antibodies form antigen-antibody complexes with antigens, and with the participation of the complement system, cause a large number of T-lymphocytes to infiltrate the orbit. T lymphocytes stimulate orbital fibroblasts to release various cytokines (mainly TNF-a2, IL-1, INF-γ, etc.), oxygen free radicals and fibroblast growth factors to promote cell regeneration and glucosaminoglucan (GAGs) synthesis, resulting in intraorbital collagen aggregation, increased connective tissue, and increased orbital contents, resulting in a series of symptoms and signs. This is known as hyperthyroidism with infiltrative proptosis. The incidence of hyperthyroidism with infiltrative proptosis is high, with about 13-45% of hyperthyroid patients having hyperthyroidism with infiltrative proptosis, which not only affects the patient’s appearance but also seriously affects the patient’s life. What are the treatments for hyperthyroidism with infiltrative proptosis? There are many ways to treat hyperthyroidism with infiltrative proptosis, but none of them has good efficacy and little toxic side effects, such as orbital decompression surgery with large side effects, orbital radiotherapy with slow effect, which usually takes several months to have obvious effect, and often requires combined immunosuppressive (hormone and methotrexate) treatment. Although immunosuppressive therapy can rapidly reduce pain, congestion and edema caused by soft tissue inflammation, and partially improve proptosis and ocular muscle paralysis and visual acuity, the toxic side effects are large, such as significant weight gain and centripetal obesity, and some patients also experience hair loss, nausea, insomnia and other toxic side effects. Other treatment methods, such as plasma exchange, immunoglobulin therapy and cytokine therapy, are not widely used in clinical practice because of their uncertain efficacy. Therefore, it is very necessary to develop drugs with good efficacy and low toxic side effects for the treatment of hyperthyroidism with infiltrative proptosis. Why can “YUNK” treat hyperthyroidism with infiltrative proptosis? ”Yunque can remove free radicals, inhibit the formation of immune complexes, protect the vitality of superoxide dismutase (SOD) in human body, regulate human immune function, especially reduce the level of thyroid receptor antibody (TRAb), thyroid microsomal antibody (TMAb) and thyroglobulin antibody (TGAb), and prevent antigenic antibodies. It prevents the production of antigen-antibody complexes, reduces cell regeneration and synthesis of glucosaminoglucan (GAGs), prevents intraorbital collagen aggregation, prevents the increase of connective tissue and ocular hypertrophy, reduces orbital contents, and reduces the symptoms and signs of hyperthyroidism with infiltrative proptosis, thus achieving the purpose of treatment. What are the advantages of “Yunker” in the treatment of hyperthyroidism with infiltrative proptosis? ”It can not only treat hyperthyroidism with infiltrative proptosis, but also rapidly reduce the pain, congestion and edema caused by soft tissue inflammation, and partially improve proptosis, ocular muscle paralysis and visual acuity, and there are no serious toxic side effects of immunosuppressive treatment. It is very safe to use without the serious toxic side effects of immunosuppressive treatment. In addition, the treatment of hyperthyroidism with infiltrative proptosis with “Yunque” is short (usually 30-60 injections), effective (with an efficiency of more than 80%), simple and acceptable to patients, and can be the drug of choice for the treatment of hyperthyroidism with infiltrative proptosis. How to use “YUNK” correctly for the treatment of hyperthyroidism with infiltrative proptosis? According to the instruction manual, take “Yunque” B agent out of the refrigerator freezer and put it at room temperature for more than 20 minutes, then inject “Yunque” A agent into B agent according to the aseptic operation, shake it for more than 1 minute to make it fully react, leave it for 5 minutes and then inject it intravenously. Inject one injection every day for 30-60 days according to the condition. Patients with serious disease, can first use “Yunque” static drip (Yunque 2 + 250ml saline) for 5-10 days, and then use “Yunque” injection treatment to improve the efficacy. After the treatment becomes effective, it can be changed to every other day injection of “Yunque” injection or 2 times a week injection of “Yunque” injection to consolidate the effect. It is also possible to use one course of treatment per month, with each course of 10 days of Yunker (2 Yunker + 250ml saline), and a total of 60 Yunker for 3 months. Does internal therapy and iodine-131 treatment of hyperthyroidism have any effect on the efficacy of Yunker in the treatment of hyperthyroidism with infiltrative proptosis? Comparative studies have shown that internal therapy and iodine-131 treatment of hyperthyroidism have no effect on the efficacy of “YUNK” in treating hyperthyroidism with infiltrative proptosis, therefore, treating hyperthyroidism with infiltrative proptosis with “YUNK” after internal therapy and iodine-131 treatment of hyperthyroidism is Therefore, the treatment of hyperthyroidism with infiltrative proptosis with “Yunque” is the ideal treatment plan. However, it is better to use Iodine-131 to cure hyperthyroidism and then use “Yunker” to treat infiltrative proptosis. After treating hyperthyroidism with infiltrative proptosis, the long-term effect of Yunque is better, and there are few cases of recurrence in the near future. This method has a positive effect, short time and quick effect, which is a more ideal treatment plan.